Laura Huppert

Dr. Laura Huppert, a medical oncologist at UCSF specializing in breast cancer, dives deep into the world of antibody-drug conjugates (ADCs). She explains how ADCs work and discusses their current use in treating HR-positive and triple-negative metastatic breast cancer. Listeners will find insights on managing ADC toxicities, the latest investigational therapies, and considerations for treatment sequencing. Huppert's enthusiasm for integrating innovations in ADCs hints at a promising future for breast cancer management.

In this discussion, Dr. Laura Huppert, a medical oncologist from UCSF, highlights key trials from SABCS 2024. She explores the INSEMA study's potential reduction of axillary surgery for early-stage hormone receptor-positive breast cancer, which could enhance patient quality of life. The conversation shifts to KEYNOTE-522, revealing the latest on Pembrolizumab and promising biomarkers for triple-negative breast cancer. Lastly, the OlympiA study shows significant gains in survival for BRCA-positive patients with Olaparib. Expert insights and practical takeaways abound!

Oncology experts discuss research on metastatic triple-negative breast cancer, including a predictive survival tool and treatment approaches like immunotherapy and antibody drug conjugates. They address challenges in diagnosing and managing complications, exploring immune-related adverse events and CNS progression. The synergy of immune checkpoint inhibitors and ADCs, optimizing treatment sequencing, patient experiences with TDXD therapy, and the role of PARP inhibitors are also highlighted.